The world of maternal healthcare has witnessed a groundbreaking development with the introduction of the Bivalent Prefusion F vaccine, a maternal vaccination against respiratory syncytial virus (RSV). This vaccine has the potential to revolutionize infant health and significantly reduce the burden of RSV-related hospitalizations.
Respiratory syncytial virus is a common pathogen that often leads to severe respiratory illnesses in infants and young children. It is a major cause of infant hospitalizations globally, with early infections potentially leading to long-term respiratory issues such as recurrent wheezing, asthma, and impaired lung function.
In England, the national maternal RSV vaccination program, initiated on September 1, 2024, has been a game-changer. The program offers the Bivalent Prefusion F vaccine to pregnant women from 28 weeks of gestation, aiming to protect newborns from the devastating effects of RSV.
A recent study presented at ESCMID Global 2026, the largest real-world study of its kind, has revealed remarkable findings. Researchers from the UK Health Security Agency (UKHSA) conducted a comprehensive analysis of linked national datasets, including NHS maternity records, immunization data, and hospital and laboratory information. The study population consisted of an impressive 289,399 infants born between September 2, 2024, and March 24, 2025, representing approximately 90% of births in England during that period.
The results are nothing short of astonishing. Across the study population, there were 4,594 RSV-associated hospitalizations. Infants born to unvaccinated mothers, despite making up only 55% of the total cohort, accounted for a staggering 87.2% of these hospitalizations. In contrast, infants whose mothers received the vaccine at least 14 days before birth experienced a significantly lower risk of hospitalization, with vaccine effectiveness estimated at an impressive 81.3% compared to the unvaccinated group.
Lead author and UKHSA epidemiologist Matt Wilson highlighted the significance of these findings, stating that this study provides robust evidence of the substantial protection offered by the vaccine against severe illness in young infants. Wilson further emphasized the importance of timing, noting that vaccine effectiveness increased as the interval between vaccination and birth lengthened, reaching close to 85% when vaccination occurred at least four weeks before delivery.
The study also focused on preterm infants, a vulnerable group at higher risk of severe RSV infection. The results were encouraging, with vaccine effectiveness estimated at 69.4% in preterm infants when allowing at least 14 days between vaccination and birth. Wilson emphasized the importance of these findings for preterm infants, stating that with sufficient time between vaccination and birth, good levels of protection can be achieved in these high-risk babies.
This study not only highlights the effectiveness of the Bivalent Prefusion F vaccine but also underscores the importance of timely vaccination during pregnancy. The implications of these findings are far-reaching, offering a glimmer of hope in the fight against RSV-related infant hospitalizations and potential long-term respiratory complications. As we continue to navigate the complexities of maternal and infant health, studies like these provide valuable insights and guide us towards innovative solutions.
